Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
Cognition Therapeutics held a productive meeting with the FDA to review Phase 2 results for zervimesine in dementia with Lewy bodies (DLB) psychosis. The company and the agency discussed the design and endpoints for a proposed registrational (Phase 3) study, establishing a clear path forward for the lead asset.
Key figures
- Drug Name
- zervimesine (CT1812)
- Phase Of Trial
- Phase 2
- Grant funding
- $200 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.